Meeting
2022 ASCO Annual Meeting
Early together: A randomized phase III study of early palliative care in metastatic uveal melanoma (MUM).
Authors
Sophie Piperno-Neumann
Medical Oncology Department, Institut Curie, Paris, France
Sophie Piperno-Neumann , Manuel Rodrigues , Timothee Marchal , Lauris Gastaud , Anne Fogliarini , Carole Bouleuc , Yves Libert , Leanne de Koning , Anne Bredart , Alexia Savignoni , Sylvie Dolbeault , Alexis Burnod
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04728113
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS9598)
DOI
10.1200/JCO.2022.40.16_suppl.TPS9598
Abstract #
TPS9598
Poster Bd #
187b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Isolated hepatic perfusion as a treatment for uveal melanoma liver metastases, first results from a phase III randomized controlled multicenter trial (the SCANDIUM trial).
First Author: Roger Olofsson Bagge
Poster
2021 ASCO Annual Meeting
Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator’s choice (IC) in first-line metastatic uveal melanoma.
First Author: Jessica Cecile Hassel
Poster
2020 ASCO Virtual Scientific Program
Percutaneous hepatic injection of rose bengal disodium (PV-10) in metastatic uveal melanoma.
First Author: Sapna Pradyuman Patel
Poster
2014 ASCO Annual Meeting
Phase II study evaluating ipilimumab as a single agent in the first-line treatment of adult patients (Pts) with metastatic uveal melanoma (MUM): The GEM-1 trial.
First Author: Jose Maria Piulats Rodriguez